A clinical of Appetol syrup in children suffering from non-specific anorexia (loss of appetite)

A clinical study to evaluate efficacy and safety of Appetol syrup in children suffering from non-specific anorexia - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2014/07/004756

Enrollment

Registered

2014-07-24

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- non-specific anorexia

Interventions

Intervention1: APPETOL SYRUP: Each 100 ml syrup contains water extracts derived from Draksha (Vitis vinifera) Trikatu (Zingiber officinale, Piper longum (Piper nigrum) Papaya satva (Carica papaya) Vi

Eligibility

Inclusion criteria

Inclusion criteria: 1 The informed consent document must be read signed and dated by subjects legally authorized representative before conducting any study procedures or examination 2 Males and females between 5 to 9 years of age 3.Subjects suffering from non specific anorexia 4.Subjects having normal vital parameters

Exclusion criteria

Exclusion criteria: 1 Children with SNAQ score less than or equal to 14 2 Children with chronic illnesses congenital abnormalities 3 Subject who is on other appetite stimulants sedatives narcotics and steroidal drugs 4 Subjects who have received treatment another investigational agent within last thirty days from Screening Visit 5 Subjects who have received chemotherapy or radiation therapy within the past 5 years 6 Subjects on systemic antibiotics or systemic therapy with cytotoxic drugs 7 Subjects having metabolic and or endocrine disorders 8 Subjects with any type of GI tract disorder including malabsorption syndrome etc 9 Subjects with liver and renal disorders 10 Subjects with known immunological, hematologic disorders or malignancy 11 Subjects having known neurological or psychiatric pathologies 12 Subjects with history of raised levels of cortisol abnormalities of thyroid hormone growth hormone and insulin secretion 13 Subject or LAR refuse to sign informed consent form 14 Subjects having a known hypersensitivity to Appetol Syrup and any of the ingredients of Appetol Syrup

Design outcomes

Primary

Measure	Time frame
To evaluate efficacy of Appetol syrup in children suffering from non-specific anorexia by assessing SNAQ ScaleTimepoint: 0 day 15 day 30 day 45 day and 60 day	—

Secondary

Measure	Time frame
1 Weight and BMI 2 Activity level on PAQ-C Scale 3 Abdominal pain abdominal distension, flatulence, constipation, nausea, vomiting 4 Overall improvement by Physician and Patientâ??s LAR at the end of the study. 5 Acceptability of drug 6 Drowsiness or sedation 7 Adverse events 8 Drug tolerability by patients LAR and physician at the end of the study Timepoint: 0 day 15 day 30 day 45 day and 60 day	—

Measure

Time frame

1 Weight and BMI 2 Activity level on PAQ-C Scale 3 Abdominal pain abdominal distension, flatulence, constipation, nausea, vomiting 4 Overall improvement by Physician and Patientâ??s LAR at the end of the study. 5 Acceptability of drug 6 Drowsiness or sedation 7 Adverse events 8 Drug tolerability by patients LAR and physician at the end of the study Timepoint: 0 day 15 day 30 day 45 day and 60 day

—

Countries

India

Contacts

Public ContactDr Arjun Kohli

ARJUN HEALTHCARE

arjunhealthcare2012@gmail.com8108829777

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026